J.C. Penney (NYSE:JCP): Deutsche Bank views Tuesday morning’s news as mixed for J.C. Penney. The firm says that while the board can return to focusing on strengthening the operations, its largest shareholder may now become a net seller of shares. Deutsche thinks that J.C. Penney shares could remain under pressure until a potential equity deal and the addition of a long-term CEO.
Eli Lilly (NYSE:LLY): Leerink believes that the positive necitumumab data revealed on Tuesday is worth $2-$3 per share as the overall survival benefit for necitumumab in front-line squamous non-small cell lung cancer is an upside surprise versus expectations — opening up a potential $1 billion-$2 billion market and assuming its full approval in 2015. Leerink has an Outperform rating on the shares.
Dick’s Sporting Goods (NYSE:DKS): Cleveland Research says that Dick’s Sporting Goods’ near-term trends remained challenging through the second quarter, and that the company has taken steps to reduce forward orders. The analyst remains positive on Dick’s longer-term and believes it is uniquely positioned for market share gains and eCommerce expansion.
Blackstone (NYSE:BX): Noting that Blackstone’s stock has tracked the S&P over the past few months, Argus believes that the company’s distribution yield will remain attractive compared to other investment options for some time. The firm reiterates a $28 price target and Buy rating on the shares.